In a report released today, Timothy Ramey from Pivotal Research reiterated a Buy rating on USANA Health (USNA), with a price target of $75. The company’s shares opened today at $63.39, close to its 52-week low of $61.26.
Ramey observed:
“We continue to hold the view that China remains a growth market over the longer-term, but we have cut estimates to reflect the new guidance and cut 2020 numbers as well, when we expect to see a return to growth in the region. Nothing fundamentally has changed regarding China, or USNA’s products in China, but the recovery from this wariness will take longer than we originally expected. It should be noted that 2020 will be a 53-week year for USNA. 2Q EPS will be reported on July 23 rd after the market’s close.”
According to TipRanks.com, Ramey is a 4-star analyst with an average return of 6.8% and a 54.3% success rate. Ramey covers the Consumer Goods sector, focusing on stocks such as Constellation Brands Inc, Post Holdings Inc, and Brown-Forman B.
USANA Health has an analyst consensus of Moderate Buy, with a price target consensus of $72.50.
See today’s analyst top recommended stocks >>
The company has a one-year high of $137.95 and a one-year low of $61.26. Currently, USANA Health has an average volume of 300.5K.
Based on the recent corporate insider activity of 87 insiders, corporate insider sentiment is negative on the stock.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
USANA Health Sciences, Inc. develops and manufactures nutritional, personal care and weight-management products. Its product line divided into four categories: Essentials, Optimizers, Foods, and Sense-beautiful science.
